Compare CVS Health Corp (CVS) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? CVS Health Corp trades at $105.9 (market cap $135.48B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $29.64. The key difference: CVS Health Corp pays a 2.51% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and CVS Health Corp is trading nearer its 52-week high, MicroSectors FANG and Innovation 3X Leveraged ETN nearer its low. Which is the better fit depends on your goals.
| CVS | FNGU | |
|---|---|---|
Market Cap | $135.48B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $106.18 | $36.15 |
52-Week Low | $58.75 | $13.73 |
Enterprise Value | $202.02B | — |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
FNGU, a leveraged ETN tracking the FANG+ Index, trades at $27.9, down 2.58% on the day. Technical indicators show a bullish moving average signal but caution from oscillators, with the 12-day RSI at 70.17 indicating potential overbought conditions. Recent news highlights extreme volatility, with a 16% single-session loss reported on June 5, 2026, underscoring the inherent risks of leveraged products.
The outlook for FNGU is highly speculative, driven by daily rebalancing and leverage amplifying both gains and losses. Investment opportunity exists for aggressive traders betting on short-term tech sector strength, but risks include rapid capital erosion during market downturns and structural costs from the 0.95% fee and leverage decay, as noted in recent financial media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →
